Study on the mechanism of Yiyi Fuzi powder in the treatment of rheumatoid arthritis based on metabolomics and network pharmacology
10.16438/j.0513-4870.2022-1146
- VernacularTitle:基于代谢组学和网络药理学探讨薏苡附子散治疗类风湿性关节炎的作用机制
- Author:
Fang-fang ZHANG
;
Xiao-kai LI
;
Xue LI
;
Yu-yu WANG
;
Jun-ke WU
;
Yu-ming WANG
;
Yu-bo LI
- Publication Type:Research Article
- Keywords:
rheumatoid arthritis;
Yiyi Fuzi powder;
metabolomics;
network pharmacology;
mechanism
- From:
Acta Pharmaceutica Sinica
2023;58(7):1802-1811
- CountryChina
- Language:Chinese
-
Abstract:
In this study, a combination of metabolomics and network pharmacology was used to study the pharmacodynamic substances and mechanism of action of Yiyi Fuzi powder (YYFZ) on rheumatoid arthritis (RA) rats. The animal experiments were conducted in accordance with the requirements of the Experimental Animal Ethics Committee of Tianjin University of Traditional Chinese Medicine (approval number: TCM-LAEC2021241). The metabolomic analysis using UPLC-Q-TOF/MS technique identified 22 metabolites, including arachidonic acid, tryptophan, linoleic acid, phenylalanine, as significant biomarkers for the treatment of RA with YYFZ, and they were significantly regressed after YYFZ treatment. The analysis of YYFZ blood components also revealed that 11 blood components, including hypaconitine, benzoylhypaconitine, and deoxyaconitine, may be the components that exert direct pharmacological effects in YYFZ in vivo, and further network pharmacological analysis of blood components obtained that YYFZ may exhibit anti-inflammatory effects through acting on PI3K/Akt signaling pathway, estrogen signaling pathway, vascular endothelial growth factor (VEGF) signaling pathway. The results of this study provide implications for the clinical application of YYFZ.
